参考文献/References:
[1]. 《中国心血管健康与疾病报告2020》编写组.《中国心血管健康与疾病报告2020》概述[J]. 中国心血管病研究,2021,19(7):582-590.
[2]. Tsujita K,Sugiyama S,Sumida H,et al. Impact of dual lipid-lowering strategy withezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention:the multicenter randomized controlled PRECISE-IVUS trial[J]. J Am Coll Cardiol,2015,66(5):495-507.
[3]. Boren J,Chapman MJ,Krauss RM,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease:pathophysiological,genetic,and therapeutic insights:a consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J,2020,41(24):2313-2330.
[4]. Tsimikas S,Gordts PLSM,Nora C,et al. Statin therapy increases lipoprotein(a) levels[J]. Eur Heart J,2020,41(24):2275-2284.
[5]. Daida H,Dohi T,Fukushima Y,et al. The goal of achieving atherosclerotic plaque regression with lipid-lowering therapy:insights from IVUS trials[J]. J Atheroscler Thromb,2019,26(7):592-600.
[6]. Mach F,Baigent C,Catapano AL,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J]. Eur Heart J,2020,41(1):111-188.
[7]. 中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中华心血管病杂志编辑委. 超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识[J]. 中华心血管病杂志,2020,48(4):280-286.
[8]. Sabatine MS,Giugliano RP,Keech AC,et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med,2017,376(18):1713-1722.
[9]. Schwartz GG,Steg PG,Szarek M,et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med,2018,379(22):2097-2107.
[10]. Iannuzzo G,Gentile M,Bresciani A,et al. Inhibitors of protein convertase subtilisin/kexin 9 (PCSK9) and acute coronary syndrome (ACS):the state-of-the-art[J]. J Clin Med,2021,10(7):1510.
[11]. Ray KK,Wright RS,Kallend D,et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med,2020,82(16):1507-1519.
[12]. O’Donoghue ML,Fazio S,Giugliano RP,et al. Lipoprotein(a),PCSK9 inhibition,and cardiovascular risk[J]. Circulation,2019,139 (12):1483-1492.
[13]. Gaudet D,Watts GF,Robinson JG,et al. Effect of alirocumab on lipoprotein(a) over≥1.5?years (from the phase 3 ODYSSEY program)[J]. Am J Cardiol,2017,119(1):40-46.
[14]. Cao YX,Liu HH,Li S,et al. A meta-analysis of the effect of PCSK9-monoclonal antibodies on circulating lipoprotein(a) levels[J]. Am J Cardiovasc Drugs,2019,19(1):87-97.
[15]. Shapiro MD,Minnier J,Tavori H,et al. Relationship between low-density lipoprotein cholesterol and lipoprotein(a) lowering in response to PCSK9 inhibition with evolocumab[J]. J Am Heart Assoc,2019,89(4):e010932.
[16]. Shapiro MD,Fazio S. PCSK9 and atherosclerosis—Lipids and beyond[J]. J Atheroscler Thromb,2017,24(5):462-472.
[17]. Petersen-Uribe ?,Kremser M,Rohlfing AK,et al. Platelet-derived PCSK9 is associated with LDL metabolism and modulates atherothrombotic mechanisms in coronary artery disease[J]. Int J Mol Sci,2021,22(20):11179.
[18]. Ding Z,Pothineni NVK,Goel A,et al. PCSK9 and inflammation:role of shear stress,pro-inflammatory cytokines,and LOX-1[J]. Cardiovasc Res,2020,116(5):908-915.
[19]. Tang ZH,Peng J,Ren Z,et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway[J]. Atherosclerosis,2017,262:113-122.
[20]. Landlinger C,Pouwer MG,Juno C,et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol,vascular inflammation,and atherosclerosis in APOE*3Leiden.CETP mice [J].?Eur Heart J,2017,38(32):2499-2507.
[21]. Bernelot Moens SJ,Neele AE,Kroon J,et al. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia[J].?Eur Heart J,2017,38(20):1584-1593.
[22]. Cao YX,Li S,Liu HH,et al. Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels:a systematic review and meta-analysis of randomised controlled trials[J].?BMJ Open,2018,8(9):e022348.
[23]. Svhmidt AF,Hunt NB,Gordillo-Mara?ón M, et al. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease[J]. Nat Commun,2021,12(1):5640.
[24]. Ruscica M,Tokg?zo?lu L,Corsini A, et al. PCSK9 inhibition and inflammation:a narrative review[J]. Atherosclerosis,2019,288:146-155.
[25]. Nicholls SJ,Puri R,Anderson T,et al. Effect of evolocumab on progression of coronary disease in statin-treated patients:the GLAGOV randomized clinical trial[J]. JAMA,2016,316(22):2373-2384.
[26]. Nicholls SJ,Puri R,Anderson T,et al. Effect of evolocumab on coronary?plaque composition[J].?J Am Coll Cardiol,2018,72(17):2012-2021.
[27]. Ako J,Hibi K,Tsujita K,et al. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome—The ODYSSEY J-IVUS trial[J].Circ J,2019,83(10):2025-2033.
[28]. Hirai K,Imamura S,Hirai A,et al. Effect of evolocumab on vulnerable coronary plaques:a serial coronary computed tomography angiography study[J]. J Clin Med,2020,9(10):3338.
[29]. Sugizaki Y,Otake H,Kawamori H,et al. Adding alirocumab to rosuvastatin helps reduce the vulnerability of thin-cap fibroatheroma:an ALTAIR trial report[J]. JACC Cardiovasc Imaging,2020,13(6):1452-1454.
[30]. Yano H,Horinaka S,Ishimitsu T. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome[J]. J Cardiol,2020,75(3):289-295.
[31]. Lee MT,Mahtta D,Dlouhy L,et al. Highlights of cardiovascular disease studies presented at the 2021 European Society of Cardiology Congress[J]. Curr Atheroscler Rep,2021,23(12):76.
[32]. Gao F,Wang ZJ,Ma XT,et al. Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography[J]. Lipids Health Dis,2021,20(1):106.
[33]. Ota H,Omori H,Kawasaki M,et al. Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques:a near-infrared spectroscopy study[J]. Eur Heart J Cardiovasc Imaging,2022,23(2):217-228.
[34]. Gao J,Liu JY,Lu PJ,et al. Effects of evolocumab added to moderate-intensity statin therapy in Chinese patients with acute coronary syndrome:the EMSIACS trial study protocol[J]. Front Physiol,2021,12:750872.
[35]. Zanchin C,Koskinas KC,Ueki Y,et al. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction:a serial,multivessel,intravascular ultrasound,near-infrared spectroscopy and optical coherence tomography imaging study—Rationale and design of the PACMAN-AMI trial[J]. Am Heart J,2021,238:33-44.
[36]. Oyama K,Furtado RHM,Fagundes A Jr,et al. Effect of evolocumab on complex coronary disease requiring revascularization[J]. J Am Coll Cardiol,2021,77(3):259-267.
[37]. Hu J,Zhao Y,Wu Y,et al. Shexiang baoxin pill attenuates ischemic injury by promoting angiogenesis by activation of aldehyde dehydrogenase 2[J]. J Cardiovasc Pharmacol,2021,77(3):408-417.
[38]. 吴帮卫,李剑,金波,等.麝香保心丸促血管新生的机制[J]. 中成药,2018,40(6):1384-1388.
相似文献/References:
[1]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(8):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[2]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(8):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[3]李天瑜 袁晋青.前蛋白转化酶枯草溶菌素9抑制剂与血小板功能[J].心血管病学进展,2021,(1):17.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
LI Tianyu,YUAN Jinqing.Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors and Platelet Function[J].Advances in Cardiovascular Diseases,2021,(8):17.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[4]石惠薇 热娜提·肉孜 刘硕霖 吴娜琼.高脂蛋白a血症的相关治疗进展[J].心血管病学进展,2021,(4):297.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.003]
SHI Huiwei,Rinat·Rozi,LIU Shuolin,et al.Lipoprotein(a)-lowering Therapy[J].Advances in Cardiovascular Diseases,2021,(8):297.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.003]
[5]林琳 李京秀 闫娜 刘丹阳 查理 金恩泽.脂蛋白a的治疗现状及研究新方向[J].心血管病学进展,2021,(6):543.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.016]
LIN Lin,LI Jingxiu,YAN Na,et al.The Therapeutic Status and Research Prospects of the Treatment of Lipoprotein a[J].Advances in Cardiovascular Diseases,2021,(8):543.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.016]
[6]许晓宇 唐炯 郑甲林.PCSK9对血管内皮功能影响的研究进展[J].心血管病学进展,2023,(6):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]
XU Xiaoyu,TANG Jiong,ZHENG Jialin.Research Progress on the Effects of PCSK9 on Vascular Endothelial Function[J].Advances in Cardiovascular Diseases,2023,(8):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]